Protalix BioTherapeutics, Inc.
PLX NYSE
SEC CIK 1006281
Follow Protalix BioTherapeutics
Weekly email: filings, results
Revenue, last quarter
$21.9M
+22.8% vs same quarter last year
Net income
$4M
+68.2% vs same quarter last year
EPS, diluted
$0.05
+66.7% vs same quarter last year
Operating cash flow
$3.9M
+204.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $52.7M | −$6.6M |
| FY24 | $53.4M | $2.9M |
| FY23 | $65.5M | $8.3M |
| FY22 | $47.6M | −$14.9M |
| FY21 | $38.4M | −$27.6M |
| FY20 | $62.9M | −$6.5M |
| FY19 | $54.7M | −$18.3M |
| FY18 | $34.2M | −$26.5M |
| FY17 | $21.1M | −$83.4M |
| FY16 | $9.2M | −$29.4M |
| FY15 | $4.4M | $58M |
| FY14 | $3.5M | −$29.9M |
| FY13 | $0 | −$27.8M |
| FY12 | $34.9M | −$11.6M |
| FY11 | $8.4M | −$36.5M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 48.8% | −10.4% | −12.5% |
| FY24 | 54.5% | 7.3% | 5.5% |
| FY23 | 64.9% | 16% | 12.7% |
| FY22 | 58.9% | −27.3% | −31.3% |
| FY21 | 57.4% | −53.4% | −71.9% |
| FY20 | 82.7% | 4.3% | −10.4% |
| FY19 | 80.1% | −19.6% | −33.4% |
| FY18 | 72.8% | −56.4% | −77.3% |
| FY17 | 19% | −163.8% | −395.9% |
| FY16 | 8.7% | −360.5% | −319.2% |
| FY15 | 83.3% | −542.4% | 1329.9% |
| FY14 | 82.1% | −810.6% | −849.9% |
| FY13 | - | - | - |
| FY12 | 75.4% | −34.9% | −33.3% |
| FY11 | 17.2% | −435.6% | −435.6% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$13.6M |
| FY24 | $7.4M |
| FY23 | −$2.5M |
| FY22 | −$25.6M |
| FY21 | −$11.7M |
| FY20 | −$26.8M |
| FY19 | −$20M |
| FY18 | −$8.4M |
| FY17 | −$11M |
| FY16 | −$32.9M |
| FY15 | −$24.7M |
| FY14 | −$30.1M |
| FY13 | −$32.5M |
| FY12 | −$1.4M |
| FY11 | −$29.3M |
- Protalix BioTherapeutics
- Healthcare median
Show the numbers
| Year | Protalix BioTherapeutics | Healthcare median |
|---|---|---|
| FY25 | −12.5% | −30.6% |
| FY24 | 5.5% | −47% |
| FY23 | 12.7% | −58% |
| FY22 | −31.3% | −80.4% |
| FY21 | −71.9% | −71.8% |
| FY20 | −10.4% | −62.2% |
| FY19 | −33.4% | −46.2% |
| FY18 | −77.3% | −49.6% |
| FY17 | −395.9% | −45.9% |
| FY16 | −319.2% | −36% |
| FY15 | 1329.9% | −37.8% |
| FY14 | −849.9% | −35.5% |
| FY13 | - | −37.1% |
| FY12 | −33.3% | −29.1% |
| FY11 | −435.6% | −27.9% |